Valens Signs Cannabidnoid Extraction and R&D Agreement with Harvest One | CashCropToday
0 Shares 81 Views

Valens Signs Cannabidnoid Extraction and R&D Agreement with Harvest One

November 14, 2018
81 Views

Valen GroWorks Corp. (CSE: VGW) (OTC-QB: MYMSF) has announced this morning that the company has entered into an agreement with Harvest One (TSXV:HVT) to provide services in relation to the extraction of cannabinoids as well as the research & development of new cannabinoid derived products.

Valen GroWorks Corp. specializes in “proprietary extraction methodologies, distillation, cannabinoid isolation and purification.” Their company focuses on offering vertically integrated services related to extraction to companies involved in the cannabis and industrial hemp industries. Whereas, Harvest One has currently focused their business model on the development of cannabinoid focused wellness products to sell to the North American market.

Under the terms of this new agreement the two companies both have something to offer the other. Valen GroWorks Corp. will supply services to Harvest One that will allow the company to continue to develop an entensive product line. Cannabinoid derived products such as beverages, topicals, vape pens, and nutraceuticals.

“We are excited for the opportunity to utilize our extraction services and R&D technology platform to support Harvest One in delivering innovative, high quality consumer packaged goods to the market,” said Tyler Robson, CEO of Valens.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
262 views
Market Watch
262 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
188 views
Global
188 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
185 views
Manufacturing
185 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: